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ABSTRACT
Background During the ﬁrst wave of pandemic H1N1
inﬂuenza in 2009, most cases outside North America
occurred in the UK. The clinical characteristics of UK
patients hospitalised with pandemic H1N1 infection and
risk factors for severe outcome are described.
Methods A case note-based investigation was
performed of patients admitted with conﬁrmed pandemic
H1N1 infection.
Results From 27 April to 30 September 2009, 631 cases
from 55 hospitals were investigated. 13% were admitted
to a high dependency or intensive care unit and 5% died;
36% were aged <16 years and 5% were aged
$65 years. Non-white and pregnant patients were over-
represented. 45% of patients had at least one underlying
condition, mainly asthma, and 13% received antiviral
drugs before admission. Of 349 with documented chest
x-rays on admission, 29% had evidence of pneumonia,
but bacterial co-infection was uncommon. Multivariate
analyses showed that physician-recorded obesity on
admission and pulmonary conditions other than asthma
or chronic obstructive pulmonary disease (COPD) were
associated with a severe outcome, as were
radiologically-conﬁrmed pneumonia and a raised
C-reactive protein (CRP) level ($100 mg/l). 59% of all
in-hospital deaths occurred in previously healthy people.
Conclusions Pandemic H1N1 infection causes disease
requiring hospitalisation of previously ﬁt individuals as
well as those with underlying conditions. An abnormal
chest x-ray or a raised CRP level, especially in patients
who are recorded as obese or who have pulmonary
conditions other than asthma or COPD, indicate
a potentially serious outcome. These ﬁndings support the
use of pandemic vaccine in pregnant women, children
<5 years of age and those with chronic lung disease.
INTRODUCTION
On 11 June 2009 the World Health Organization
announced the ﬁrst inﬂuenza pandemic of the 21st
century.
1 2 While most pandemic H1N1 infections
were mild or subclinical, the case fatality rate was
0.1e0.7%.
34Early reports suggested a case hospi-
talisation rate of 2e8%,
5e9 later moderated to
approximately 1% in view of under-ascertainment
of mild cases.
10 Although atypical, patients with
severe disease imposed a considerable burden on
hospital systems. Hospitalisation due to pandemic
H1N1 infection was most common in children,
teenagers and younger adults. At least half had
underlying medical conditions.
128 e12 Relatively
few studies have examined the risk factors associ-
ated with a severe outcome.
71 3
METHODS
Data collection
The Inﬂuenza Clinical Information Network (FLU-
CIN) surveillance network was established by the
Department of Health in England on 11 May 2009.
Clinical data were collected from 55 hospitals in 20
cities or towns (see ﬁgure 1 in online supplement).
Trained FLU-CIN data collectors gathered infor-
mation from the case notes of patients hospitalised
with pandemic H1N1 infection without pre-selec-
tion. All patients had acute respiratory illness and
pandemic H1N1 infection conﬁrmed by real-time
reverse-transcriptase PCR. Diagnostic tests were
performed as dictated by clinical management.
Data were extracted using a standard form that
included demographic characteristics, past medical
history, prehospital medication, clinical presenta-
tion, care timelines, initial assessment (emergency
department and/or acute medical unit), investiga-
tions and care escalation from levels 0 to 3,
i
discharge and death. Since height and weight are
not uniformly recorded in UK hospital notes,
obesity based on physicians’ observations was
captured when recorded on admission.
Analysis of data
Anonymised data were analysed using STATA
Version 10 (StataCorp). c
2 or Fisher exact tests
were used to assess differences in proportions and
the ManneWhitney test was used for continuous
variables. The demographic data were compared
with those of the combined populations of London,
East Midlands and Northern Ireland because these
areas provided >75% of the FLU-CIN cases. As
< Supplementary ﬁgures are
published online only. To view
these ﬁles please visit the
journal online (http://thorax.bmj.
com).
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i Level 0: Patients whose care needs can be met through normal
ward care. Level 1: Patients at risk of deteriorating or recently
relocated from higher levels of care whose needs can be met on an
acute ward with additional advice and support from the critical care
team. Level 2: Patients requiring more detailed observation or
intervention including support for a single failing organ system and
those ‘stepping down’ from higher levels of care (high dependency
unit). Level 3: Patients requiring advanced respiratory support alone
or basic respiratory support together with support of at least two
organ systems. This includes all complex patients requiring support
for multiorgan failure (intensive care unit).
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Respiratory infectionpaediatric normal reference ranges for respiratory rate and blood
pressure vary with age, and heart rate also varies with body
temperature, abnormal values in children (aged <16 years) were
deﬁned after appropriate adjustment.
14e17
Univariate analysis was performed using logistic regression to
identify factors affecting the risk of requiring enhanced care
(levels 2 or 3) or death in hospital (or both) as a combined
measure of severe outcome. Unadjusted odds ratios (Wald test)
and 95% CIs were computed. A multivariable regression tech-
nique was applied using all statistically signiﬁcant variables
identiﬁed during univariate analysis, including exploration for
robustness and interactions using likelihood ratio tests. Age
(continuous variable) was forced into each model, being an
a priori confounder for comorbid conditions and case fatality.
Two separate models were constructeddone for demography,
comorbidities and clinical characteristics and one for selected
investigations and other prognostic indicators. Where contin-
uous variables (eg, serum C-reactive protein (CRP)) were found
to be signiﬁcant, these were converted into categorical variables
to facilitate clinical interpretation. A peripheral oxygen satura-
tion threshold of 94% (breathing air) was selected based on
British Thoracic Society recommendations for the instigation of
supplemental oxygen therapy.
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RESULTS
A total of 631 hospitalised cases with H1N1 infection (226
children, 405 adults; median age 23 years; range 3 monthse90
years) admitted between 27 April and 30 September 2009 are
described. The onset of illness, available for 522 patients,
occurred from April 25 to September 29 (see ﬁgure 2 in online
supplement). Most cases were non-white (table 1) and the
distribution of age and ethnicity differed substantially from the
source population. Of the 631 patients, 284 (45% overall; 34%
children and 51% adults) had one or more underlying medical
conditions (table 2), of which asthma was most common in
children (16%) and adults (31%). Of 159 subjects with asthma,
88 (55%) regularly used oral or inhaled steroids. Twenty-seven
patients were pregnant, representing 4% of total admissions and
18% of admissions among women aged 16e44 years (table 2).
Two, 13 and 8 pregnancies were in the ﬁrst, second and third
trimesters, respectively (missing data, n¼4), and 8 (30%) had
one or more underlying medical conditions. Obesity was
recorded on admission in 8 (2%) of 405 adults; no child was
noted to be obese.
Preadmission care
The median interval between onset of illness and admission
recorded for522cases was2 days(range 0e33; interquartilerange
0e24). It was shorter in children than in adults (1 day vs 2 days,
p<0.001) but was unaffected by comorbid conditions (median 2
vs 2 days; p¼0.42). Twenty children (9%) and 62 adults (15%)
received antiviral drugs before admission (p¼0.02). Preadmission
antiviral drugs were given to 35 patients (12%) with comorbidity
and to 47 patients (14%) without comorbidity (p¼0.80).
Clinical presentation, treatment and outcome
Patients presented most frequently with fever (71%), cough
(68%), breathlessness (36%), headache (27%), sore throat (23%)
and nausea or vomiting (22%) in adults; and fever (74%), cough
(50%) and nausea or vomiting (27%) in children. Overall, 11%
presented with diarrhoea, which was almost twice as common
in white ethnic groups (15.4% vs 8.1%; p¼0.008) in both adults
(16% vs 9%) and children (14% vs 7%).
Upon presentation, 63% of children and 87% of adults had
tachycardia and 30% of children and 33% of adults had
tachypnoea (table 3). About half had fever ($388C); 16% of
children and 24% of adults had a peripheral oxygen saturation of
<94% breathing air, and 13% of children and 24% of adults had
systolic hypotension. Alanine aminotransferase was raised in
19% of children and 34% of adults. Increased levels of CRP of
<100 mg/l occurred in 19% of children and 31% of adults;
increases of $100 mg/l occurred in 8% of children and 18% of
adults. Eighteen patients (3%) presented with symptoms of
encephalitis (new behavioural change, meningism, focal signs,
seizures or confusion), one of whom died. Twenty-nine patients
(5%) presented with muscle weakness or tenderness suggestive
of myositis, of whom one died.
Pneumonia
Chest radiographic results were recorded in the notes in 349
cases (106 children, 243 adults), of which 37 children (35%) and
65 adults (27%) had ﬁndings consistent with pneumonia.
Thirty-seven of 65 adults had sufﬁcient data to derive a CURB65
score of 0, 1 and 2 in 15 (41%), 17 (46%) and 5 (14%) cases,
respectively. The median age of patients with pneumonia was
26 years; 46 (45%) had one or more underlying medical condi-
tions, 4 were pregnant and 2 were obese. Initial arterial blood gas
analysis readings (while breathing room air) were available from
34 patients with pneumonia; 1/23 (4%) with an arterial oxygen
tension $8 kPa died compared with 3/11 (27%) with an initial
reading <8k P a( p ¼0.085).
The occurrence of radiological pneumonia was unrelated to
the presence of underlying medical conditions (p¼0.09). Of the
102 cases with radiological pneumonia, 14 (6 children) had
received preadmission antiviral drugs (14%) compared with 28/
247 (11%) patients (2 children) without pneumonia on the chest
x-ray (p¼0.53). The median length of stay for patients with
Table 1 Demographic characteristics of 631 UK patients hospitalised
with pandemic H1N1 infection during the ﬁrst pandemic wave compared
with source population data
n (%)
Population
comparison* (%)
Sex: female 320 (51) 51.3
Age (years)
<1 42 (7) 1.2
1e4 59 (9) 5.2
5e15 125 (20) 14.2
16e24 114 (18) 11.7
25e34 83 (13) 16.9
35e44 75 (12) 15.4
45e54 68 (11) 12.3
55e64 32 (5) 9.4
65e74 22 (3) 7.3
>75 11 (2) 6.4
Ethnicityy
White 202 (38) 81.9
Mixed 7 (1) 2.1
Asian/Asian British 169 (31) 8.0
Black/Black British 100 (19) 6.3
Chinese and other 59 (11) 1.7
Data are number (%) unless otherwise indicated.
*Data for comparison of sex, age structure and ethnicity (London, East Midlands and
Northern Ireland combined) were obtained from the Ofﬁce for National Statistics (www.
statistics.gov.uk) and Northern Ireland Statistics and Research Agency (www.nisra.gov.uk):
National Census 2001 data: KS01 sex, KS02 age structure, KS06 ethnicity and
corresponding census area statistics (CAS) data: UV03, UV04 and UV09 (available on
Neighbourhood Statistics and www.nomis.co.uk) for further subdivisional data.
yInformation on ethnicity was unavailable for 94 cases; assessments of ethnicity are based
on 537 cases.
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Respiratory infectionpneumonia was 6 days compared with 3 days for patients
without pneumonia (p¼0.0001). Thirty-seven of 102 patients
(36%) required level 2 (n¼6) or level 3 (n¼31) care, 21 (21%)
underwent mechanical ventilation (intubated) and 12 (12%)
died, of whom 11 were ventilated. Mortality in cases with
radiographic pneumonia was signiﬁcantly higher than in cases
without (OR 4.57, 95% CI 1.71 to 12.18; p¼0.0008). Four cases
of pneumonia (4%) had positive bacteriological ﬁndings. Two
children with severe developmental delay and extreme prema-
turity, respectively, grew methicillin-resistant Staphylococcus
aureus (MRSA) and one adult grew Streptococcus pneumoniae in
sputum; all three died. One adult had S aureus bacteraemia and
survived.
Inpatient treatment
After admission, antiviral drugs were prescribed to 474 patients
(75%) and 366 (58%) received antibiotics. One hundred and
forty-seven of 157 cases (93%) who did not receive an antiviral
drug in hospital did not receive an antiviral agent before hospi-
talisation. One hundred and fourteen patients (18%) received
steroids as an acute intervention; of these, 71 had underlying
asthma, 57 of whom were previously maintained on steroids.
The 43 patients without asthma treated in hospital with
steroids included 13 with COPD or other chronic lung disease on
long-term steroids; 7 on steroids for other long-term conditions
(eg, myeloma); 8 with sudden deterioration (of whom 4 were
pregnant or recently post-partum); 5 with wheeze on admission;
2 obese patients; 2 with suspected new asthma; and 1 suspected
allergic reaction (the reason for steroid treatment was unclear in
5 cases).
Length of stay
The median length of hospital stay was 3 days in children (range
1e32; interquartile range 1e28) and 4 days in adults (range
1e41; interquartile range 1e29; p¼0.004); it was unaffected by
comorbidity or treatment with antiviral drugs before hospital-
isation.
Deaths, severity criteria and requirement for critical care
Overall, 85 of the 631 cases (14%) had a severe outcome. Eighty
patients received level 2 (n¼27) or level 3 (n¼53) care and 29
died. The recorded case fatality rate was 4.6%, 3.5% in children
and 5.2% in adults (likelihood ratio¼1.5, p¼0.34). Seventeen of
the 29 fatalities (59%) were previously healthy. The median age
of those who died was 49 years in adults and 7 years in children.
There were no signiﬁcant differences in use of level 2 or level 3
care with age; however, the in-hospital case fatality rate
increased with age (<5 years (3%), 5e15 years (4%),
16e44 years (3.7%), 45e64 years (9%), $65 years (6.0%)) and
was signiﬁcantly higher in patients aged $45 years (3.6% vs
8.3%; p¼0.02). Twenty-ﬁve patients (31%) died while in level 2
or level 3 care. A further two deaths occurred on standard wards
(a patient with metastatic carcinoma and another with severe
chronic lung disease), one in the emergency room (after 4 h
resuscitation) and one after transfer to another hospital (no
subsequent information). Of cases receiving level 2 or level 3
care, those who died received a median of 10 days care at this
level whereas survivors received 3 days of care (p¼0.001). No
patients were declined level 2 or level 3 care for non-clinical
reasons during the study period.
Recipients of antiviral drugs before admission were less likely
to require level 2 or level 3 care (8/82 (9.8%) vs 72/549 (13%);
likelihood ratio¼0.72, p¼0.394) or to die (2/82 (2.4%) vs 27/549
(4.9%); likelihood ratio¼0.48, p¼0.31) than non-recipients, but
both trends were non-signiﬁcant. Two of 27 pregnant women
(7%) died in hospital while in level 3 care; four others (15%)
received level 2 (n¼1) or level 3 (n¼3) care and survived.
Table 4 shows the association between admission variables
and severe outcome. Altered conscious level, dyspnoea, require-
ments for intravenous ﬂuids or supplementary oxygen, radio-
logically-conﬁrmed pneumonia and CRP levels $100 mg/l were
each associated with a severe outcome, as were obesity recorded
on admission and chronic pulmonary disease other than asthma
or COPD (eg, cystic ﬁbrosis, ﬁbrosing alveolitis and congenital
lung defects). In a multivariable model of demography, comor-
bidities and clinical characteristics, obesity recorded on admis-
sion and pulmonary conditions other than asthma or COPD
were found to be associated with a severe outcome (table 5). An
additional multivariable analysis of selected investigations and
possible prognostic indicators showed that radiologically-
conﬁrmed pneumonia and a CRP level $100 mg/l were inde-
pendently signiﬁcant (table 5). The addition of further variables
did not signiﬁcantly alter either model.
DISCUSSION
The strengths of this study include conﬁrmation by standardised
PCR criteria, relatively few missing data and a setting in which
hospitalisation and management of cases is driven by national
guidelines.
19 Reported cases were followed up without selection.
Except in Scotland, the acquisition of cases closely mirrored the
national epidemic curve geographically and temporally, with
most occurring in Greater London, the English Midlands and
Table 2 Prehospital comorbidity in 631 patients hospitalised with
pandemic H1N1 infection during the ﬁrst pandemic wave compared with
national prevalence data
Children
(n[226)
Adults
(n[405)
All admissions
(n[631)
Background
prevalence* (%)
No. of comorbiditiesy
0 149 (66) 198 (49) 347 (55) e
1 66 (29) 138 (34) 204 (32) e
$2 11 (5) 69 (17) 80 (13) e
Comorbidity
Cardiovascular disease 5 (2) 64 (16) 69 (11) 3.5
Pulmonary disease
COPD 0 (0) 25 (6) 25 (4) 1.5
Asthma 35 (16) 124 (31) 159 (25) 5.9
Other pulmonary disease 8 (3) 13 (3) 21 (3) -
Diabetes 3 (1) 48 (12) 51 (8) 4.1
Other metabolic disease 4 (2) 2 (<1) 6 (1) -
Neurological disease 9 (4) 10 (3) 19 (3) -
Cerebrovascular disease 0 (0) 3 (<1) 3 (<1) 1.7
Obesity recorded on
admission
0 (0) 8 (2) 8 (1) 8.1z
Pregnancy 0 (0) 27 (7)x 27 (4) 6.2{
Data are number (%) unless otherwise indicated.
*National prevalence data on comorbidity were obtained from the Quality and Outcomes
Framework (QOF) primary care data for 2009 (ww.qof.ac.nhs.uk) and are based on all ages
except for pregnancy.
yRecorded obesity and pregnancy are excluded from the number of comorbidities in the
upper portion of the table.
zNational prevalence data on obesity based on QOF obesity registers deﬁned as body mass
index $30 kg/m
2.
x27 pregnancies represent 7% of all adults but 18% of women aged 16e44 years in the
study.
{6.2% of females aged 15e44 years estimated to be pregnant in source population: in
addition to 207474 live births in London, East Midlands and Northern Ireland in 2008, we
assumed that 4% of females aged 15e44 years experienced miscarriage or abortion in the
same time period (119668). To calculate the prevalence of pregnancy we took 9/12 of
annual live births (assuming 9-month duration of pregnancy) and 3/12 of miscarriages/
abortions (assuming 3-month duration), divided by the total female population aged
15e44 years.
COPD, chronic obstructive pulmonary disease.
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Respiratory infectionNorthern Ireland (see ﬁgures 1 and 2 in the online supplement).
Overall, 12% of patients required high dependency or intensive
care and 4.6% died; the mortality among those requiring
enhanced care was 31%.
The median age of cases was 23 years and 46% had risk factors
for seasonal inﬂuenza complications. In relation to the source
population, hospitalisations were highest in those aged <5 years
and lowest in those aged $55 years, consistent with the age-
speciﬁc prevalence of cross-reacting antibodies.
20 Similar to other
reports,
13 mortality was signiﬁcantly higher above 44 years of
age.
Over one-half of all admissions and 59% of all in-hospital
deaths occurred in previously healthy people. In contrast,
Donaldson et al found that 36% of patients who died had no
(19%) or only mild (17%) underlying illnesses.
21 The principal
comorbidity was asthma (in adults and children). About 45% of
hospitalised patients with asthma with pandemic H1N1 infec-
tion did not routinely use inhaled or oral steroids, suggesting
that pandemic inﬂuenza vaccine (H1N1) might be beneﬁcial for
all patients with asthma rather than just those with more severe
disease.
Pregnancy substantially increases the risks for severe respira-
tory illness and excess deaths during pandemics and seasonal
inﬂuenza,
22 and in our series pregnant women comprised 18% of
admissions among women aged 16e44 years compared with an
expected prevalence of 6% in the source population. These
ﬁndings suggest that pregnant women are about three times
more likely to be admitted to hospital with H1N1 infection than
non-pregnant women of similar age and conﬁrm the importance
of vaccinating pregnant women, which may also protect their
newborn infant.
23
Obesity has been previously identiﬁed as a risk factor for
severe pandemic H1N1 infection.
13 24 25 Obesity recorded on
admission was identiﬁed as an independent risk factor for
a severe outcome. This observation possibly reﬂects that gross
(as opposed to mild) obesity is more likely to be recorded by
physicians in case notes and the lack of reserve respiratory
capacity in such individuals.
Univariate analyses showed that patients with a severe
outcome were more likely to be recorded as obese and to have
pulmonary disease other than asthma or COPD (eg, cystic
ﬁbrosis, ﬁbrosing alveolitis and congenital lung defects), altered
consciousness level, shortness of breath, radiologically-conﬁrmed
pneumonia, CRP level $100 mg/l, peripheral oxygen saturation
of <94% on air or to have required supplemental oxygen or
intravenous ﬂuids on admission than those managed on stan-
dard wards. These ﬁndings are similar to those of previous
studies
7 13 and highlight the importance of regular monitoring
Table 3 Presenting signs and initial investigations and the percentage that were abnormal in patients hospitalised with pandemic H1N1 infection
during the ﬁrst pandemic wave
Observations n Mean Range Interquartile range Level of abnormality %
Temperature (8C)
Children 183 38.0 35.3e41.4 36.0e40.1 37.1e37.9 22
$38.0 50
Adults 344 39.0 35.1e40.2 35.9e40.3 37.1e37.9 24
$38.0 53
Pulse (rate/min)
Children 97 137 54e240 89e184 > Normal* 63
Adults 218 107 54e184 62e155 >85 87
Pulse (respirations/min)
Children 94 37 18e98 20e66 > Normal 30
Adults 205 23 10e44 14e40 >30 33
Systolic BP (mmHg)
Children 32 106 83e126 93e119 < Normal 13
Adults 216 125 68e191 84e185 <110 24
Diastolic BP (mmHg)
Children 33 60 39e90 42e77 < Normal 36
Adults 217 71 32e121 43e100 <65 32
C-reactive protein (mg/l)
Children 98 60 1e322 4e146 31e99 19
$100 8
Adults 208 57 1e322 1.5e274 31e99 31
$100 18
White cell count (310
9/l)
Adults and children 425 9.0 1.1e38.0 1.1e32.9 >11.0 17
Children 102 44 3e163 19e82 >195 0
Adults 285 91 5e800 7e611 >200 3
Urea (mmol/l)
Children 104 7.2 0.6e106 1.1e40 >6.4 14
Adults 286 7.3 0.9e130 1.5e56 >6.7 18
Alanine transaminase (IU/l)
Children 70 42.7 2e393 7e177 >40 19
Adults 179 36.3 8e167 10e127 >35 34
SpO2 (%, breathing room air)
Children 175 95.9 54e100 80e100 <94% 16
Adults 334 95.1 66e100 60e100 <94% 24
*See Methods for derivation of abnormal values in children.
SpO2, peripheral oxygen saturation.
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Respiratory infectionfor dyspnoea and peripheral oxygen saturation. Multivariable
analysis of clinical features revealed that obesity recorded on
admission and pulmonary conditions other than asthma or
COPD remained signiﬁcant clinical risk factors for a severe
outcome. In addition, radiologically-conﬁrmed pneumonia and
CRP levels $100 mg/l were independently associated with
a severe outcome. In general, CRP levels are higher in patients
with bacterial infections than in those with non-bacterial
infections, and high levels are associated with mortality.
26 Our
ﬁndings should alert physicians to the possibility of very high
CRP levels in patients with pandemic H1N1 infection and its
potential seriousness. In our study, 29% of patients with chest
x-rays had ﬁndings consistent with pneumonia. The median
duration of stay of these patients was twice as long as those
without pneumonia, and mortality in cases with radiographic
pneumonia was several fold higher than for the whole case series
(12% vs 4.6%). Bacterial co-infections were less commonly
reported than in other case series,
27 28 although we did not
access autopsy data.
29
Higher rates of severe pandemic H1N1 infection have been
reported in indigenous or disadvantaged populations,
24 30 31 as
also occurred during 1918e19.
32 In our study, the number of
Asian and black people who were admitted exceeded population
estimates of ethnic proﬁle 3e4-fold. The reasons for this excess
are unclear, but could include language barriers affecting
consulting behaviour or treatment access, overcrowding,
household size and genetic susceptibility.
Fewer than one-sixth of all children and adults in this case
series, including those with underlying medical risk factors for
complications, received antiviral drugs before admission; this
requires further investigation. In this case series, 25% were not
prescribed antiviral drugs during the admission for reasons that
are unclear; in most cases (93%) they did not receive an antiviral
drug before hospital admission either. While the median interval
between illness onset and hospital admission was just 1 day in
children and 2 days in adults, 28% of children and 23% of adults
in our study were apyrexial on admission, while just over half
had a fever of $388C. Such ﬁndings question the appropriate-
ness of specifying fever of at least 388C as part of the clinical case
deﬁnition in current diagnostic, treatment and infection control
algorithms.
Table 4 Analysis of comorbidity, demography, clinical characteristics and selected investigations as
risk factors for severe outcome in patients hospitalised with pandemic H1N1 infection during the ﬁrst
pandemic wave
People affected by condition or feature
(number with severe outcome) Likelihood ratio (95% CI) p Value
Age (years) e 1.01* (0.99 to 1.02) 0.089
Asthma 159 (18) 0.77 (0.44 to 1.34) 0.360
COPD 25 (6) 2.10 (0.81 to 5.43) 0.123
Chronic pulmonary conditions, excluding
asthma or COPD
21 (7) 3.41 (1.33 to 8.71) 0.010
Cardiovascular disease 69 (12) 1.41 (0.72 to 2.75) 0.314
Diabetes 51 (7) 1.02 (0.44 to 2.35) 0.956
Neurological disorders 19 (3) 1.21 (0.34 to 4.25) 0.764
Hepatic disease 7 (2) 2.60 (0.49 to 13.65) 0.257
Obesity recorded on admission 8 (4) 6.96 (1.46 to 27.28) 0.008
Smoker (current and former)z 103 (16) 1.01 (0.53 to 1.91) 0.972
Pregnancy 27 (6) 1.87 (0.73 to 4.77) 0.190
White ethnicityyz 202 (29) 1.08 (0.65 to 1.78) 0.764
Altered conscious level 10 (6) 1.11 (1.04 to 1.17) 0.001
Dyspnoea 181 (44) 1.32 (1.81 to 1.49) 0.001
Heart rate (abnormal)y 198 (31) 1.62 (0.80 to 3.30) 0.180
Respiratory rate (abnormal)y 89 (16) 1.78 (0.89 to 3.56) 0.102
Required supplemental oxygen on
admission
99 (33) 4.51 (2.72 to 7.40) 0.001
Intravenous ﬂuid replacement on
admission
145 (28) 1.76 (1.07 to 2.89) 0.005
Radiologically-conﬁrmed pneumonia 102 (37) 5.28 (2.95 to 9.47) 0.001
CRP $100 mg/ly 46 (16) 4.41 (2.14 to 9.10) 0.001
SpO2 <94% on airy 107 (31) 3.60 (2.17 to 6.27) 0.001
*Reﬂects a 1% increase in risk of severe outcome for each additional year of age.
yInformation about smoking history was documented for 216 cases; ethnicity was recorded for 537 cases; heart rate, with
corrections for temperature, was available for 512 cases; respiratory rate was recorded for 470 cases; chest radiography ﬁndings
were recorded for 349 cases; CRP levels were recorded for 306 cases; SpO2 data were recorded for 252 cases.
z45 severe outcomes among 335 non-white patients.
COPD, chronic obstructive pulmonary disease; CRP, C-reactive protein; SpO2, peripheral oxygen saturation.
Table 5 Results of logistic regression analyses of (A) demography,
comorbidities and clinical characteristics and (B) selected investigations
and other possible prognostic indicators for critical care requirement or
death in hospital
Odds ratio (95% CI) p Value
(A) Clinical conditions*
Obesity recorded on admission 6.08 (1.45 to 25.37) 0.013
Chronic respiratory disease other than
asthma or COPD
3.17 (1.22 to 8.24) 0.018
(B) Other clinical parametersy
Radiologically-conﬁrmed pneumonia 4.97 (2.09 to 11.81) 0.001
C-reactive protein >100 mg/l 3.06 (1.20 to 7.81) 0.019
*Multivariable analysis of demography, comorbidities and clinical characteristics was
constructed based on observations from 631 cases.
yA separate multivariable analysis was constructed for selected investigations and other
possible prognostic indicators based on observations from 193 cases.
COPD, chronic obstructive pulmonary disease.
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Respiratory infectionThe median length of stay in hospital was 3 days in children
and 4 days in adults, which was unaffected by comorbidity or
the use of antiviral drugs before admission. While cases that
received antiviral drugs before admission were less likely to
require high dependency or intensive care and were 50% less
likely to die in hospital, neither trend was signiﬁcant. A number
of other studies now suggest that early treatment with oselta-
mivir may reduce the likelihood of hospitalisation and death due
to pandemic H1N1 inﬂuenza.
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Conclusions
While most patients with pandemic H1N1 inﬂuenza experience
mild disease, 12% of those admitted to hospital require high
dependency or intensive care, about 30% have radiographic
pneumonia and 5% die. Pandemic H1N1 inﬂuenza should be
considered in the differential diagnosis of any respiratory illness
while the pandemic virus is circulating in the community; fever
$388C is a poor discriminator. Patients admitted to hospital
with illness compatible with inﬂuenza should have a chest x-ray
on admission and should be actively monitored for altered level
of consciousness, dyspnoea and low peripheral oxygen satura-
tion. An abnormal chest x-ray or raised CRP leveldespecially in
patients who are observed to be obese, have pulmonary condi-
tions other than asthma or COPD or are pregnantdmay suggest
a potentially serious outcome. Our ﬁndings support the use of
H1N1 pandemic vaccine in pregnant women, children aged
<5 years and those with chronic lung disease as a priority,
including patients with asthma, regardless of severity.
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